MiMedx Group (MDXG) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting called to order virtually, with board and management expressing appreciation for shareholder attendance.
Meeting format included business proceedings followed by a Q&A session.
Director nominees and senior management introduced; voting procedures and agenda outlined.
Board and executive committee updates
Seven director nominees presented and nominations closed with no other candidates.
Acknowledgment of outgoing board members for their leadership and service.
Shareholder proposals
Election of seven directors to the board.
Advisory vote on executive compensation (say-on-pay) as required by Dodd-Frank Act.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MiMedx Group
- Surgical growth and the Sanara deal target ~$400M revenue and >20% margins.MDXG
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum - Sanara deal targets a larger Surgical platform as Q3 sales rose 9% YoY.MDXG
Investor presentation - Surgical growth and cost cuts lifted EBITDA as Wound sales plunged and Sanara review dragged on.MDXG
Q3 2026 - Sanara MedTech acquisition for $350M targets $400M+ 2027 revenue and 20%+ EBITDA margin.MDXG
Q2 2026 & M&A announcement - Strong growth, product innovation, and regulatory tailwinds position the business for long-term success.MDXG
Cantor Global Healthcare Conference 2025 - Regulatory reform and strategic expansion drive optimism for growth amid reimbursement challenges.MDXG
2024 Cantor Fitzgerald Global Healthcare Conference - Strong sales growth, new product launches, and robust governance highlighted in 2025.MDXG
Proxy filing - Director elections, say-on-pay, and auditor ratification headline the 2026 annual meeting.MDXG
Proxy filing - Q1 2026 sales fell 33% as wound care plunged 60% and surgical rose 13%, prompting cost cuts.MDXG
Q1 2026